Get started
Author

Clay Parker

ORCID: 0009-0000-4975-8603
Observed ORCID: 0009-0000-4975-8603
OpenAlex ID: A5027753934
Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy
2021 · Brian T. Hill, Caroline J Roth, et al. · Blood · 13
Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop
2023 · Magdalena Czader, Catalina Amador, et al. · American Journal of Clinical Pathology · 10
PDF
Progression of follicular lymphoma and related entities: Report from the 2021 SH/EAHP Workshop
2023 · Amy S Duffield, Ahmet Dogan, et al. · American Journal of Clinical Pathology · 9
PDF
Mutations of ATM Confer a Risk of Inferior Survival in Patients with TP53-wild Type Mantle Cell Lymphoma
2022 · Jean L. Koff, Rachel Kositsky, et al. · Blood · 7
Clinical Validation of Duoseq, a Novel Assay for Clinical DNA and RNA Sequencing
2025 · Elizabeth Thacker, Lanie Happ, et al. · Journal of Molecular Diagnostics · 2
Characterising the genomic landscape of two clinical risk groups in CD30+ T-cell lymphoproliferative disorders with cutaneous involvement: a multi-institutional retrospective study
2026 · Leonardo P.A. Biral, Veronica Russell, et al. · EBioMedicine · 1
Abstract 3910: The Atlas of Blood Cancer Genomes: A resource for therapeutic and biomarker development
2024 · Jennifer Shingleton, Raju Pillai, et al. · Cancer Research · 1
Development and validation of Duoseq as a novel diagnostic and companion assay for lymphoma and other cancers.
2022 · Chrissie Rozzi, Stacey O'Neill, et al. · Journal of Clinical Oncology · 1
Primary mediastinal large B-cell lymphoma genomic profiling demonstrates thymic B-cell identity and frequent aberrant somatic hypermutation
2026 · Rebecca J. Leeman-Neill, Leonardo P.A. Biral, et al. · Cancer Research Communications
Data from Elucidating the Gene Expression Signature of Rosai–Dorfman Disease: A Study from the Atlas of Blood Cancer Genomes Initiative
2026 · Sheren Younes, Fadzai Chinyengetere, et al.
Supplementary Figure S4 from Elucidating the Gene Expression Signature of Rosai–Dorfman Disease: A Study from the Atlas of Blood Cancer Genomes Initiative
2026 · Sheren Younes, Fadzai Chinyengetere, et al.
Figure 3 from Elucidating the Gene Expression Signature of Rosai–Dorfman Disease: A Study from the Atlas of Blood Cancer Genomes Initiative
2026 · Sheren Younes, Fadzai Chinyengetere, et al.
Supplementary Figure S2 from Elucidating the Gene Expression Signature of Rosai–Dorfman Disease: A Study from the Atlas of Blood Cancer Genomes Initiative
2026 · Sheren Younes, Fadzai Chinyengetere, et al.
Supplementary Figure S3 from Elucidating the Gene Expression Signature of Rosai–Dorfman Disease: A Study from the Atlas of Blood Cancer Genomes Initiative
2026 · Sheren Younes, Fadzai Chinyengetere, et al.
Table 1 from Elucidating the Gene Expression Signature of Rosai–Dorfman Disease: A Study from the Atlas of Blood Cancer Genomes Initiative
2026 · Sheren Younes, Fadzai Chinyengetere, et al.
Supplementary Figure S1 from Elucidating the Gene Expression Signature of Rosai–Dorfman Disease: A Study from the Atlas of Blood Cancer Genomes Initiative
2026 · Sheren Younes, Fadzai Chinyengetere, et al.
Figure 2 from Elucidating the Gene Expression Signature of Rosai–Dorfman Disease: A Study from the Atlas of Blood Cancer Genomes Initiative
2026 · Sheren Younes, Fadzai Chinyengetere, et al.
CRC-25-0834_supplementary_table_ST1-ST4 from Elucidating the Gene Expression Signature of Rosai–Dorfman Disease: A Study from the Atlas of Blood Cancer Genomes Initiative
2026 · Sheren Younes, Fadzai Chinyengetere, et al.
Supplementary Figure S5 from Elucidating the Gene Expression Signature of Rosai–Dorfman Disease: A Study from the Atlas of Blood Cancer Genomes Initiative
2026 · Sheren Younes, Fadzai Chinyengetere, et al.
Figure 1 from Elucidating the Gene Expression Signature of Rosai–Dorfman Disease: A Study from the Atlas of Blood Cancer Genomes Initiative
2026 · Sheren Younes, Fadzai Chinyengetere, et al.
Elucidating the Gene Expression Signature of Rosai–Dorfman Disease: A Study from the Atlas of Blood Cancer Genomes Initiative
2026 · Sheren Younes, Fadzai Chinyengetere, et al. · Cancer Research Communications
PDF
Establishing clinical performance characteristics for Duoseq, a new assay for DNA and RNA sequencing.
2023 · Elizabeth Thacker, Magdalena Czader, et al. · Journal of Clinical Oncology
P115: Distinct signaling pathways and checkpoint molecule expression across histological subtypes of nodular lymphocyte-predominant Hodgkin lymphoma
2022 · Ilja Kalashnikov, Rachel Kositsky, et al. · HemaSphere
Works count: 23
Citation count: 44
H-index: 4
I10-index: 2
Year
Topic
Type